Product Information
| Molecular Weight | 491.4 g/mol |
| Purity | >97% |
| Molecular Formula | C18H23N5O8P • Na |
| CAS | 16980-89-5 |
| Solubility | Soluble in DMSO at 50 mg/mL or water at 50 mg/mL. |
Dibutyryl-cAMP (sodium salt), also known as bucladesine, is an analog of the second messenger cyclic adenosine 3'5'-monophosphate (cAMP). Dibutyryl-cAMP is a phosphodiesterase (PDE) inhibitor and a cAMP-dependent protein kinase (PKA) activator that mimics the action of cAMP in cells (1). The anti-inflammatory activity of Dibutyryl-cAMP makes it an option for the treatment of skin inflammation (2). Exposure of rat glial cells to Dibutyryl-cAMP inhibited cell growth and increased glial fibrillary acidic protein levels, resulting in a change toward an astrocytic phenotype (3). Treatment of rat hepatocytes with Dibutyryl-cAMP suppressed both iNOS mRNA and protein expression, decreased iNOS promoter activity, and reduced DNA binding of the transcription factor NF-κB (4). Dibutyryl-cAMP treatment increased phosphorylated cAMP-response element-binding protein (p-CREB) via protein kinase A (PKA) signaling in rat pulmonary fibroblasts. Cells treated with Dibutyryl-cAMP exhibited a reduced number and size of silicosis nodules, and inhibited myofibroblast differentiation and extracellular matrix deposition (5).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 35857S | 25 mg |
|
